Iovance provides updates on Amtagvi (lifileucel)
In its latest (Q2) earnings report, Iovance confirmed plans to reduce its workforce by 19% in a bid to save $100 million in yearly costs due to lower… read more.
In its latest (Q2) earnings report, Iovance confirmed plans to reduce its workforce by 19% in a bid to save $100 million in yearly costs due to lower… read more.
In a large-scale multinational study involving over 400,000 women and men aged 37 to 70 years from six European countries, researchers from the University of Vienna, in collaboration… read more.
Thanks to new advances in cancer care, more and more people are surviving cancer, with a projected total of 22.5 million survivors by 2032. The need for proper… read more.
Precigen, Inc. announced that the FDA has approved Papzimeos (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). Papzimeosis the first and only FDA-approved therapy… read more.
The evidence supporting the health benefits of breastfeeding is overwhelming, yet many women taking medicines are being advised to stop, often unnecessarily, according to a new study from… read more.
Iovance Biotherapeutics Inc. announced Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Amtagvi (lifileucel), a tumor-derived autologous T cell immunotherapy. Amtagvi is indicated for… read more.
People who have had COVID-19 are at increased risk of developing certain inflammatory diseases of the airways, such as asthma, hay fever and chronic sinusitis. However, vaccination against… read more.
The FDA has updated Skysona’s indication, allowing it to be used only in patients who do not have an available human leukocyte antigen (HLA)-matched donor for stem cell… read more.
Artificial intelligence (AI) can help emergency department (ED) teams better anticipate which patients will need hospital admission, hours earlier than is currently possible, according to a multi-hospital study… read more.
The human papillomavirus (HPV) can cause six types of cancer. It’s responsible for almost all cervical cancer cases. HPV now causes the majority of oropharyngeal (throat) cancers. It… read more.
Novo Nordisk announced that the FDA has approved an additional indication for Wegovy (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic… read more.
Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of surgical complications linked to their obesity, a new study… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.